Biolase Technology announced preliminary financial results for the second quarter of 2009. The company expects revenue to exceed $13.5 million, rebounding from the previous quarter. Gross margins are expected to return to historic ranges of 45-55% compared to 27% last quarter. Operating expenses will continue to reflect cost reduction programs. The company anticipates reporting net income and positive cash flow for the second quarter.

1. FORM 8-K
BIOLASE TECHNOLOGY INC - BLTI
Filed: July 07, 2009 (period: July 07, 2009)
Report of unscheduled material events or corporate changes.

2. Table of Contents
8-K - LIVE FILING
Item 2.02 Results of Operations and Financial Condition.
Item 9.01 Financial Statements and Exhibits.
SIGNATURES
Exhibit Index
EX-99.1 (EX-99.1)

3. UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): July 7, 2009
Biolase Technology, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
Delaware 000-19627 87-0442441
_____________________ _____________ ______________
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
4 Cromwell, Irvine, California 92618
_________________________________ ___________
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: 949-361-1200
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Source: BIOLASE TECHNOLOGY I, 8-K, July 07, 2009

4. Top of the Form
Item 2.02 Results of Operations and Financial Condition.
On July 7, 2009, Biolase Technology, Inc. (the "Company") issued a press release announcing preliminary financial results for the second quarter ended June 30,
2009.
A copy of the Company's press release is filed as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
d) Exhibits.
99.1 Press Release of Biolase Technology, Inc., dated July 7, 2009.
This Current Report on Form 8-K and the information contained in the press release shall not be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information
in this Current Report on Form 8-K and the press release is not incorporated by reference into any filings of the Company, whether
made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in the filing, unless
explicitly incorporated by specific reference into such filing.
Source: BIOLASE TECHNOLOGY I, 8-K, July 07, 2009

5. Top of the Form
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Biolase Technology, Inc.
July 7, 2009 By: /s/ David M. Mulder
Name: David M. Mulder
Title: Chief Executive Officer
Source: BIOLASE TECHNOLOGY I, 8-K, July 07, 2009

6. Top of the Form
Exhibit Index
Exhibit No. Description
99.1 Press Release of Biolase Technology, Inc., dated July 7, 2009.
Source: BIOLASE TECHNOLOGY I, 8-K, July 07, 2009

7. NEWS RELEASE for July 7, 2009
BIOLASE ANNOUNCES PRELIMINARY SECOND QUARTER RESULTS
IRVINE, CA (July 7, 2009) — BIOLASE Technology, Inc. (NASDAQ:BLTI), the world’s leading dental laser
company, today announced that, based on a preliminary review of its financial performance for the second
quarter ended June 30, 2009, the Company expects to report:
• Net revenue estimates exceeding $13.5 million for the 2009 second quarter, rebounding from $6.6 million
in the previous quarter.
• Gross margins as a percentage of revenue for the 2009 second quarter returning to more historic ranges of
between 45 percent and 55 percent, as compared to 27 percent in the previous quarter.
• Operating expenses continuing to reflect the impact of cost reduction programs recently completed.
• Net income and cash flows to be positive for the 2009 second quarter.
BIOLASE Chief Executive Officer David M. Mulder said, “During difficult economic times — when our
doctors need it most — we have worked very hard alongside our primary partner Henry Schein, Inc.
(NASDAQ: HSIC) to spread the benefits of Waterlase*Dentistry across the world. Our new distribution
commitments, aggressive new sales and marketing programs, and our new Waterlase MD Turbo TM launch
were all key factors in recent improvements. We continue to look strategically to the future and continue to
invest in research and development on our annual $4 million R&D plan, but given the current economic
environment we remain cautious in our expectations and vigilant on cost-control measures.”
The Company will provide additional details on a quarterly conference call and webcast when it reports full
financial results in August.
About BIOLASE Technology, Inc.
BIOLASE Technology, Inc. (http://www.biolase.com), the world’s leading dental laser company, develops,
manufactures and markets Waterlase technology and lasers and related products that advance the practice of
dentistry and medicine. The Company’s products incorporate patented and patent pending technologies
designed to provide clinically superior performance with reduced pain, faster and biological recovery times.
BIOLASE’s principal products are dental laser systems that perform a broad range of dental procedures,
including cosmetic and complex surgical applications. Other products under development address
ophthalmology, pain management and other medical and consumer markets.
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of
1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be
identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,”
“will,” and variations of these words or similar expressions. Forward-looking statements are based on management’s current,
preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company’s actual results to
differ materially from the statements contained herein, and are described in the Company’s reports it files with the Securities and
Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking
statements. Such information is subject to change, and we undertake no obligation to update such statements.
For further information, please contact: Jill Bertotti, of Allen & Caron, +1-949- 474-4300.
####
Source: BIOLASE TECHNOLOGY I, 8-K, July 07, 2009

8. _______________________________________________
Created by 10KWizard www.10KWizard.com
Source: BIOLASE TECHNOLOGY I, 8-K, July 07, 2009